a b s t r a c t MicroRNAs (miRNAs) are a class of endogenous, non-coding, 18-24 nucleotide length singlestrand RNAs that could modulate gene expression at post-transcriptional level. Previous studies have shown that miR-128 enriched in the brain plays an important role in the development of nervous system and the maintenance of normal physical functions. Aberrant expression of miR-128 has been detected in many types of human tumors and its validated target genes are involved in cancer-related biological processes such as cell proliferation, differentiation and apoptosis.
Introduction
MicroRNAs (miRNAs) are a family of small non-coding singlestranded RNAs. The primary function of miRNAs is to act as negative regulators of gene expression at post-transcriptional level [1] . lin-4, the first discovered miRNA in 1993, regulated the development of Caenorhabditis elegans via repressing expression level of lin-14 protein [2] . Another miRNA let-7 was demonstrated to mediate the post-transcriptional regulation of its target gene expression [3] . It is known that miRNAs are identified virtually in all multicellular organisms including plants, worms, arthropods, and vertebrates [4] , which can be either clustered or dispersed in the genome. To date, there have been more than 4000 mature miRNAs found in humans, which regulate about 30% of mammalian protein-coding genes. In general, miRNAs suppress the mRNA translation or degrade the target mRNAs through the interaction between 5′-"seed" region of the miRNA and its perfectly complementary sequences located in the 3′-UTRs of mRNAs [5] [6] [7] . Since Liu and coworkers first reported that the missing or amplified of miRNA expression in breast cancer tissue frequently was correlated with the vulnerable regions in human chromosome [8] , accumulated evidence had showed that miRNA genes were frequently located near genomic fragile as well as in cancer-associated genomic regions [9] . Aberrant expression of many miRNAs could be observed in most tumor types and some were also related with the degree, stage, prognosis and therapeutic response to malignant tumors [10, 11] . It has been demonstrated that miRNAs regulate the expression of their target genes related to tumorigenesis and metastasis, including cell cycle regulation, differentiation, apoptosis and invasion [12] . Some have oncogenic characteristics and others appear as tumor-suppressor. Therefore, miRNAs could also be divided into two groups: oncogenic and tumor suppressor-like [13, 14] .
MicroRNA-128 (miR-128) is a brain-enriched miRNA. It has been found that the expression of miR-128 has tissue-specific and developmental-specific expression patterns, mainly in neurons rather than in atrocities [15] , and it is abundantly represented in the hippocampal region of fetal, adult and Alzheimer's disease brain [16] . It has been demonstrated that miR-128 plays an important role in the development of nervous system and maintenance of its normal physical functions [17] . The aberrant expression of miR-128 could also be detected not only in tissues but also in blood of some malignant tumor patients [18, 19] . The roles and mechanisms of miR-128 with its target genes in tumorigenesis and metastasis will be reviewed as follows.
miR-128 gene
Location and expression of miR-128 gene miR-128 is a kind of intronic miRNAs and encoded by two distinct genes, miR-128-1 and miR-128-2, which are embedded in the introns of R3HDM1 (R3H domain containing 1) and RCS (ARPP-21, cyclicAMP-regulated phosphoprotein, 21 kDa) genes located on human chromosome 2q21.3 and 3p22.3 respectively [20] . Both miR-128-1 and miR-128-2 are processed to generate the same mature miRNAs with identical sequence, miR-128. It is also known that majority of intronic miRNAs transcriptionally depend on their host gene expression and processed from the same primary transcript [21] , which makes them to be conserved across some species and mediates synergistic and antagonistic regulatory effects [22] . However, researchers also showed that about 26% of the mammalian intronic miRNAs might be transcribed from their own promoters [23] . Monteys et al. demonstrated that miR-128-2 had Pol III promoter in its 5′-flanking region, which might permit an independent expression of its host gene ARPP-21 [24] . Simultaneously Muinos-Gimeno et al. also found that there were three SNPs located in the genomic region corresponding to hsa-mir-128-1-R3HDM1, and there was a strong geographical genetic variation among different populations from HapMap [25] .
Expression of miR-128 in malignant tumors
Aberrant expression of miR-128 can be observed in many kinds of malignant tumors. In hematopoietic malignant tumors, Zhu measured the levels of miR-128 expression in the blood of 147 newly diagnosed acute leukemia patients and found that miR-128 was highly expressed in acute lymphoblastic leukemia (ALL) patients, whereas there was no significant difference between acute myeloid leukemia (AML) patients and normal controls. They speculated miR-128 was associated with the diagnosis and prognosis of acute leukemia [26] . Fulci et al. reported that different levels of miR-128 could be used to discriminate B-lineage ALL subgroups harboring specific molecular lesions [27] . More strikingly, the down-regulation of miR-128 in AML patients was correlated with mutations in nucleophosmin (NPM1) [28] . Underexpression of miR-128 was also observed in glioma as compared to tumor-adjacent brain devoid of tumors or age-matched controls, and particularly in more aggressive subtype such as glioblastoma multiforme (GBM) and medulloblastoma based on miRNA array, northern blot or qRT-PCR analyses [29] [30] [31] [32] [33] . Conversely, the expression level of miR-128 was obviously increased in blood of glioblastoma patients [19] . However, the levels of miR-128 expression in the other solid tumor tissues were obviously different. Volinia and his colleagues measured 540 different kinds of malignant tumor samples and found that the expression of miR-128b was significantly up-regulated in tumor tissues of colon, lung and pancreatic cancer through a large-scale miRnome analysis [18] . In contrast, Katada and his colleagues measured the expression levels of miR-128 in the specimens of 42 undifferentiated gastric cancer tissues and paired controls. Their findings showed that mir-128a was up-regulated in undifferentiated gastric cancer tissues while mir-128b was down-regulated [34] . Khan et al. measured 21 independent prostate specimens (seven benign prostatic hyperplasia, eight prostate cancers, and six metastatic prostate cancers) and the results displayed a significant reduction in the levels of miR-128 from benign prostatic hyperplasia to prostate cancer to metastatic prostate cancer in a progressive fashion [35] . Similar results could also be detected in more invasive ovarian cancer cells than less invasive ones [36] . Among 57 breast cancer patients by in situ hybridization, Zhu et al. found that the expression of miR-128 was reduced in the chemoresistant tumor tissues but increased in the chemosensitive tissues. Furthermore they demonstrated that the level of miR-128 expression in breast cancer tissues was correlated with the response of breast tumor patients to novel adjuvant chemotherapy and the survival of patients [37] .
Mechanisms for miR-128 expression in tumor tissues
Based on miRNA processing, mature miRNAs are initially transcripted by RNA polymerase II or III to form an endogenous transcript (pri-miRNA); pri-miRNAs undergo processing by RNase III enzyme Drosha and Dicer in the nucleus and change into pre-miRNAs; pre-miRNAs are exported into the cytoplasm by Ran-GTP dependent exportin-5, followed by further processing [38] . Therefore, several factors could influence miR-128 expression.
Loss of heterozygosity (LOH) or amplification located in miR-128 gene
LOH refers to the absence of functional gene in the lost region, and amplification refers to having an increased genomic copy number. LOH or amplification of total or part of chromosome commonly occurred in cancer tissues, and both of them could induce the alteration in the number of gene copies. It was reported that LOH at chromosome 3p could be detected in 87% of primary breast cancers [39] . Qian measured the expression of miR-128-2 and its host gene ARPP21 mRNA by qPCR in 21 breast cancer specimens and 15 benign breast disease tissues, and found that the expression of ARPP21 mRNA was significantly decreased in breast cancer tissues compared with control specimens, and similar expression pattern were observed in pri-miR-128-2 and mature miR-128. They also demonstrated that miR-128-2 expression was significantly in accordance with that of its host gene ARPP21 [40] . LOH at chromosome 3p could also be detected in 96% of the lung cancers and 78% of preneoplastic/preinvasive bronchial epithelium [41] . Moreover, miR-128 expression could not be detected in non-small cell lung cancer cell lines and in clinical non-small cell lung cancer tissues [42] .
Point mutation or SNP existed in miR-128 gene
Kotani and his colleagues noticed that miR-128 gene, which was cloned and sequenced from a cell line derived from an MLL-AF4 ALL patient, had a single nucleotide change A13G, located 13 bp from the 3′ end of mature miR-128b. They further demonstrated this mutation in miR-128 gene caused a significant block in the processing of miR-128b and a reduction in the level of the mature miR-128b [43] . Besides this, Muinos-Gimeno et al. also showed that R3HDM1 gene displays SNP among populations [25] .
Epigenetic alteration of miR-128 gene
DNA methylation in promoter regions may cause down-regulation of the miRNA gene expression. In order to investigate the difference of miR-128 expression between ALL and AML patients, Mi et al. tested DNA methylation status of CpG-island located at miR-128b promoters in 10 ALL, 14 AML, and three normal samples, and they found that the average methylation rate of the ALL group was 2.7%, lower than that of the AML group (17.1%). This result suggests that up-regulation of miR-128b in ALL patients might be due to low degree of CpG-island methylation in promoter regions [44] .
Regulated by transcriptional factors
It is known that SNAIL is a zinc finger transcriptional repressor, which is usually expressed at high levels in tumors and exerts oncogenic functions. It could down-regulate the expression of miR-128 by directly binding to its promoter regions of both E-box 1 and 2 [40] . Forced expression of SNAIL reduced not only the expression levels of mature miR-128 and pri-miR-128 but also the expression of their host gene ARPP mRNA. Donzelli et al. noticed that p53R175H, a hotspot p53 mutant, could induce miR-128-2 expression. They also found that mutant p53 protein, which is characterized by increased stability and prolonged half-time period, could bind to the putative promoter of miR128-2 host gene ARPP21 and increase the expression of both miR-128 and ARPP21 mRNA [45, 46] .
Changes of miRNA-associated genes and their proteins during miRNA processing
It was reported that several miRNA-associated genes and their proteins such as Drosha, DGCR8, Dicer etc could regulate miRNA processing [38] . Therefore, it was speculated that the expression of miR-128 might also be influenced.
Roles of miR-128 in tumorigenesis and development
Numerous researches have demonstrated that miR-128 can regulate proliferation, differentiation and apoptosis of various tumor cells via targeting several genes such as Bmi-1 that are mainly related with PI3K-AKT-mTOR signal pathway, indicating miR-128 plays an important role in tumorigenesis and development [47, 48] .
Inhibiting tumor proliferation
Transcription factor Bmi-1(B lymphoma mouse moloney leukemia virus insertion region-1) is critical for the cell-cycle progression, and it can act as a positive regulator for DNA damage response and mitochondrial function [49] . It is also essential for promoting selfrenewal of several types of normal and cancer stem cells [50] [51] [52] [53] . Up-regulation of Bmi-1 frequently occurs in many types of tumor cells. It was demonstrated that Bmi-1 could regulate cell growth in glioma cells by using transgenic mice [54] . Godlewski found that the expression of miR-128 could be detected in brain, but not in glioma cells, whereas the expression of Bmi-1 protein was up-regulated in glioblastoma tissue, but not in normal brain. Overexpression of miR-128 could significantly reduce glioma cell proliferation in vitro and glioma xenograft growth in vivo, accompanied by a decrease in histone methylation (H3K27me(3) ) and Akt phosphorylation, and up-regulation of p21(CIP1) levels, consistent with Bmi-1 downregulation. Moreover, miR-128 was able to specifically block glioma self-renewal by directly targeting Bmi-1 [55] . Papagiannakopoulos and his colleagues observed that increased miR-128 expression was capable of repressing growth and mediating differentiation of glioma, while decreased miR-128 expression could be correlated with aggressive human glioma subtypes. Furthermore they found that miR-128 could repress glioma-initiating neural stem cells (giNSC) self-renewal and enhance neuronal differentiation by targeting oncogenic receptor tyrosine kinases (RTKs), epithelial growth factor receptor (EGFR) and platelet-derived growth factor receptor-α (PDGFRα). Finally they demonstrated that miR-128 could repress gliomagenesis by using an autochthonous glioma mouse model [56] . In another study, Venkataraman and his colleagues discovered that miR-128a could increase intracellular ROS level by targeting Bmi-1 and inhibit medulloblastoma cell growth by promoting senescence [57] . Palumbo demonstrated that Bmi-1 could affect aggrssive growth-hormone(GH)-inducing pituitary tumor cell proliferation by binding to PTEN promotor directly [58] , thereby inbiting the expression of PTEN, a negative regulator of the PI3K/AKT/mTOR signaling pathway. In contrast, overexpression of miR-128 could inhibit the proliferation of glioma cell through targeting p70S6K1, a kind of serine/threonine kinase and one of the key downstream targets of mammalian rapamycin (mTOR). Up-regulation of miR-128 could also suppress the expression of HIF-1 and VEGF, which were p70S6K1 downstream molecules [59] . It was also reported that miR-128 could also repress the proliferation of glioma cells by directly targeting transcription factor E2F3 [60] . Besides, it is noticed that miR-128a was up-regulated in the letrozole-resistant breast cancer cells with loss of the sensitivity to transforming growth factor β (TGFβ), whereas inhibition of endogenous miR-128a resulted in re-sensitization of the letrozole-resistant cells to TGFβ growth inhibitory effects. This result implies that miR-128a could directly target transforming growth factor receptor I (TGFβRI) and play an important role in regulating TGFβ signaling pathways and survival of the letrozole-resistant cells involved in breast cancer progression and aromatase inhibitors-resistance [61] .
Promoting tumor cell differentiation
It is known neurotrophins (NT) and their receptors are key factors in regulating neuronal differentiation and survival, and they are also related with the synaptic plasticity and neuronal cell survival during development and mature. Neurotrophic tyrosine kinase receptor type 3 (NTRK3) is a functional receptor for neurotrophin 3 (NT3), and it consists of two major isoforms: FL-NTRK3 (fulllength NTRK3) and TR-NTRK3 (truncated isoform of NTRK3). The former has the activity of kinase while the latter is non-catalytic, which has been verified to affect membrane remodeling, cytoskeletal reorganization and cell movement [62, 63] . Guidi studied the role of miR-128 in the differentiation process of glioma by using a glioblastoma cell model to ATRA. They found that overexpression of miR-128 could induce glioblastoma cell differentiation with rounded bodies and shorter neuritis etc morphology changes, and increase the total number of differentiated cells. The results indicated that ATRA promoted glioblastoma cell differentiation accompanied by the up-regulation of miR-128 with targeting TR-NTRK gene directly. When miR-128 was overexpressed, the expression of several genes such as Bcl-2 was upregulated. Therefore, miR-128 could function in the differentiation process of glioblastoma associated with cell survival [64] .
Influencing apoptosis and drug resistance
Zhu and his colleagues noticed that miR-128 was significantly reduced in chemoresistant breast tumor initiating cells (BT-IC) enriched by mammosphere cultures or CD44 þ CD24 À fluorescenceactivated cell sorting from breast cancer cell lines SK-3rd and MCF-7 and primary breast tumors, accompanied by an overexpression of Bmi-1 and ABCC5(multidrug resistance-associated protein 5). Reduction in miR-128 might contribute to chemotherapeutic resistance in breast cancer. They also found that ectopic expression of miR-128 could increase apoptosis and DNA damage via direct targeting Bmi-1 and ABCC5 protein expression in BT-ICs when cooperating with doxorubicin [37] . It is known that p53 mutations have profound effects on non-small-cell lung cancer (NSCLC) resistance to chemotherapeutic treatments, and mutant p53 proteins, usually expressed at high levels in tumors, where they exert oncogenic functions [46] . Donzelli observed that the increased expression of miR-128-2 could inhibit lung cancer cells apoptosis and increases resistance to cisplatin, doxorubicin and 5-fluorouracyl treatments. Further they demonstrated that miR-128-2 could target E2F5 at post-transcriptional level and lead to the abrogation of its repressive activity on p21 (waf1) transcription, where it exerted an antiapoptotic effect by preventing pro-caspase-3 cleavage. These results suggest that miRNA-128-2 plays a master role in NSCLC chemoresistance [45] .
Regulating EMT and inhibiting tumor cell invasion and motility
Epithelial-to-mesenchymal transition (EMT) is a process in which epithelial cells lose characteristic epithelial traits while gaining some properties of mesenchymal cells. Recent studies have indicated that EMT might play an important role in cancer invasion and metastasis [65] . Qian and his colleagues demonstrated that overexpression of miR-128 induced morphological transformation of MDA-MB-231 cells, from a spindle fibroblast-like mesenchymal shape to a cobblestone-like epithelial morphology, accompanied by decreasing in both total cell number and colony formation number in soft agar, as well as a retarded wound closing and a reduction in cell migration and invasion compared with the control cells. This indicated that miR-128 could inhibit the transformation of mammary epithelial cells [40] . It is known that DCX is a microtubule-associated protein and Reelin is an extracellular matrix glycoprotein secreted by Cajal-Retzius cells, and both of them are involved in the migratory potential of neuronal cells. By using cell model of neuroblastoma cell differentiation, Evangelisti and his colleagues found that the expression of miR-128 was greatly increased in SH-SY5Y cells after ATRA treatment, while the repression of Reelin and DCX was inhibited. They found that ectopic overexpression of miR-128 could down-regulate glioblastoma cell invasion by directly targeting Reelin and DCX [66] . By contrast, overexpression of miR-128 in ovarian cancer cells resulted in reduction of cellular motility and adhesion through direct targeting colony stimulating factor-1 (CSF-1) [36] .
Perspective
Aberrant expression of miR-128 in a broad type of tumor cells indicates that miR-128 plays an important role in tumorigenesis and cancer development. This miRNA may be considered not only as a key biomarker for diagnosis and prognosis of cancers, but also as an effective agent for targeted therapy of malignant tumors. Understanding the mechanisms of miR-128 and its target genes underlying tumor proliferation, differentiation, apoptosis, invasion and metastasis provides important cues to develop novel therapeutic strategies for cancer prevention and treatment. Therefore, the information generated from this review will explore the potential of miR-128 as a promising therapeutic strategy for cancer therapy in future.
